AN EVIDENCE-BASED APPROACH TO MANAGING ACS PATIENTS FOR OPTIMAL CARE
FACULTY
C. Michael Gibson, MS, MD, FACC
Director TIMI Core Laboratories and Data Coordinating Center
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts
Steven R. Steinhubl, MD (Moderator)
Associate Professor of Medicine
Director of Cardiovascular Education & Clinical Research
University of Kentucky Chandler Medical Center
Lexington, KY
PURPOSE STATEMENT
An Evidence-Based Approach to Managing ACS Patients for Optimal Care will discuss current ACS treatment guidelines and recent clinical trials, and evaluate the role of antithrombin and antiplatelet therapy in the management of STEMI and NSTE-ACS patients.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Discuss the current guideline recommendations for antithrombin and antiplatelet therapy for the adjunctive treatment of STEMI and NSTE-ACS.
- Summarize the results of the most recent trials of antithrombin and antiplatelet agents for use in the management of STEMI and NSTE-ACS patients.
- Incorporate recent trial results into an evidenced-based management plan for patients with STEMI or NSTE-ACS
TARGET AUDIENCE
This activity is intended for clinical and interventional cardiologists, as well as emergency medicine physicians and other healthcare professionals interested in the management of acute coronary syndromes.
ACCREDITATION INFORMATION
Expiration date: June 26, 2008
Physicians: Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Med-IQ designates this educational activity for a maximum of
1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses (CBRN): Med-IQ is a provider approved by the California Board of Registered Nursing, Provider Number CEP #14745, for 1.0 Contact Hours.
Pharmacists: 
1 contact hour (0.100 CEU) of credit for pharmacists. Pharmacy credits made possible by the cosponsorship of Med-IQ and Medical Education Collaborative (MEC). MEC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. For questions about pharmacy accreditation, contact MEC at 303 420 3252 or e-mail inquire@mecce.org. Enduring ACPE # 815-999-07-018-H01. The program is designed for all pharmacists.
Other Credit Information
Nurse Practitioners: Med-IQ is accredited by ACCME to provide continuing medical education for physicians, and will provide nurse practitioners who successfully complete the activity with a Statement of Participation indicating that the activity was designated for 1 AMA PRA Category 1 CreditTM.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 CreditTM for the PRA from organizations accredited by ACCME.
Disclosure Policy
It is the policy of Med-IQ that everyone in a position to control the content of an educational activity discloses all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will be disqualified from all aspects of this CME activity. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this program has been peer reviewed and has been approved for compliance. The faculty have indicated the following financial relationship(s), which have been resolved through an established COI resolution process, and have stated that these reported relationship(s) will not have any impact on their ability to give an unbiased presentation.
C. Michael Gibson
Fees received for promotional/non-CME activities: sanofi-aventis U.S., GlaxoSmithKline, The Medicines Co., Genentech
Contracted research: sanofi-aventis U.S.
Steven R. Steinhubl
Consulting fees/advisory boards: The Medicine Company, Eli Lilly and Company, sanofi-aventis U.S. Daiichi Sankyo, Inc.
Med-IQ Disclosure
Reshma Carter has disclosed that her spouse is an employee of Novartis Pharmaceuticals.
All other employees of Med-IQ have no financial relationships to disclose.
MEC Disclosure
The employees of Medical Education Collaborative have no financial relationships to disclose.
Acknowledgement of Commercial Support
This educational series is supported by an educational grant from sanofi-aventis U.S.